Q1 2016 13F Holders as of 31 Mar 2016
-
Type / Class
-
Debt / NOTE 0.750% 8/1
-
Market price (% of par)
-
152.44%
-
Total 13F principal
-
$245,697,000
-
Principal change
-
+$75,400
-
Total reported market value
-
$373,336,000
-
Number of holders
-
22
-
Value change
-
-$1,423,530
-
Number of buys
-
7
-
Number of sells
-
13
Institutional Holders of LIGAND PHARMACEUTICALS INC - NOTE 0.750% 8/1 as of Q1 2016
As of 31 Mar 2016 LIGAND PHARMACEUTICALS INC - NOTE 0.750% 8/1 had 22 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of $245,697,000 principal (par value or face value) of the bond of the company.
Largest 10 bondholders included LINDEN ADVISORS LP, CAMDEN ASSET MANAGEMENT L P /CA, WOLVERINE ASSET MANAGEMENT LLC, CITADEL ADVISORS LLC, Allianz Asset Management AG, LAZARD ASSET MANAGEMENT LLC, DEUTSCHE BANK AG\, BASSO CAPITAL MANAGEMENT, L.P., WELLS FARGO & COMPANY/MN, and CALAMOS ADVISORS LLC.
This table shows 22 bond principal holders of the security as of 31 Mar 2016.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.